ESTIMATED
05/14/2024
05/14/2024
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.62 | -$0.62 | -$0.62 |
Q2 2024 | 3 | -$0.63 | -$0.58 | -$0.61 |
Q3 2024 | 1 | -$0.64 | -$0.64 | -$0.64 |
Q4 2024 | 1 | -$0.64 | -$0.64 | -$0.64 |
Q1 2025 | 1 | -$0.67 | -$0.67 | -$0.67 |
Q2 2025 | 1 | -$0.67 | -$0.67 | -$0.67 |
Q3 2025 | 1 | -$0.69 | -$0.69 | -$0.69 |
Q4 2025 | 1 | -$0.69 | -$0.69 | -$0.69 |
AN2 Therapeutics, Inc. last posted its earnings results on Tuesday, May 14th, 2024. The company reported $-0.56 earnings per share for the quarter, topping analysts' consensus estimates of $-0.61 by $0.05. The company had revenue of 0 for the quarter and had revenue of 0 for the year. AN2 Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.74 diluted earnings per share) and currently has a price-to-earnings ratio of -0.97. AN2 Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/14/2024 | Q1 2024 | -$0.61 | -$0.56 | 0.05 | $0 | $0 | 03/29/2024 | Q4 2023 | -$0.57 | $0 | $80,000 | 11/09/2023 | Q3 2023 | -$0.63 | -$0.65 | -0.02 | $0 | 08/10/2023 | Q2 2023 | -$0.85 | -$0.81 | 0.04 | $0 | 05/11/2023 | Q1 2023 | -$0.68 | -$0.75 | -0.07 | $0 | 03/29/2023 | Q4 2022 | -$0.63 | -$0.66 | -0.03 | $0 | 11/09/2022 | Q3 2022 | -$0.59 | -$0.56 | 0.03 | $0 | 08/11/2022 | Q2 2022 | -$0.45 | -$0.50 | -0.05 | $0 | 05/10/2022 | Q1 2022 | -$0.52 | -$2.39 | -1.87 | $0 | 12/31/2021 | Q4 2021 | -$0.42 | $0 | 09/29/2021 | Q3 2021 | -$0.49 | $0 | 06/29/2021 | Q2 2021 | -$0.36 | $0 | 03/30/2021 | Q1 2021 | -$0.15 | $0 |
---|
A. AN2 Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates.
A. In the previous quarter, AN2 Therapeutics, Inc. (NASDAQ:ANTX) reported $-0.56 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.61 by $0.05.
A. The conference call for AN2 Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for AN2 Therapeutics, Inc.'s latest earnings report can be read online.
A. AN2 Therapeutics, Inc. (NASDAQ:ANTX) has a recorded net income of $0. AN2 Therapeutics, Inc. has generated $-2.74 earnings per share over the last four quarters.
A. AN2 Therapeutics, Inc. (NASDAQ:ANTX) has a price-to-earnings ratio of -0.97 and price/earnings-to-growth ratio is 0.03.